Clinical Trials Directory

In this study, people will take a special medicine called PLX-61639 one time each day. Before starting, there will be a time called the screening period that can last up to 28 days. During this time, doctors will check to see if you can join the study. After that, you will take the medicine in 28-day cycles. You will go to the clinic often for check-ups. These visits will include blood tests, heart tests, and scans. Some visits might take the whole day. You will also write in a diary to keep track of when you take the medicine. The amount of medicine you get may be different depending on when you join the study. You can stay in the study as long as the doctor thinks the medicine is helping you.

We are doing this study to find out if the combination of an experimental drug called ONC201 (the study drug) with paxalisib is an effective option for patients with a diffuse midline glioma (DMG). We also want to see how much of these drugs are absorbed by tumor tissue in patients with brain tumors.

This study is for people with type 1 diabetes (T1D). Their immune system attacks cells in the body that make insulin. A new treatment called GNTI-122 is made from their own blood cells and may help stop this attack. People will be in one of three groups: low dose, high dose, or high dose with another medicine called rapamycin. The study includes several visits to check if the treatment works and is safe.

The person in the study will take part for about 5 years and 2 months. During this time, doctors will check their health in many ways. These checks include a physical exam, blood tests, breathing tests, heart tests, muscle scans, and other special tests. The study has four parts: 1. First, there is a screening visit to make sure the person can join. 2. Next, the person will get the study medicine. 3. Then, there is an active observation period for 1 year. During this time, there will be about 19 visits at home and at the clinic. 4. Finally, there is a long-term follow-up for 4 years. This part has 8 visits.

We are doing this study to find out if adding azithromycin to the routine single antibiotic preventative therapy can lower the risk of developing infections after a cesarean delivery.

We are doing this study to learn more about how 2 different classes of diabetes medications help lower the risk of heart disease. The types of diabetes medications that have been shown to reduce the risk of new or worsening heart disease are SGLT2 inhibitors and GLP-1 receptor agonists. We don't know which of these drugs might be preferable to reduce heart disease risk for diabetes patients, and we hope this study can help us find out which drug(s) may be the most appropriate for most patients.

We are doing this study to help develop a tool that doctors can use to figure out who might be at risk for developing muscle spasticity after a stroke. Spasticity is abnormal muscle stiffening that can lower people's strength and ability to move well. We hope this tool can help doctors catch this problem early and start treatment sooner to make therapy more effective.

We are doing this study to get a better understanding of what predicts severe pain in teenagers and young adults living with sickle cell disease.